Trial Profile
A Randomized, Double Blind, Dose-finding Study of Inhaled Oligosaccharide (OligoG) vs Placebo in Patients With Cystic Fibrosis
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II/III
Latest Information Update: 04 Jul 2022
Price :
$35
*
At a glance
- Drugs OligoG (Primary)
- Indications Cystic fibrosis
- Focus Registrational; Therapeutic Use
- Acronyms SMR3372
- Sponsors AlgiPharma
- 27 Jun 2022 Planned End Date changed from 10 Jul 2022 to 1 Nov 2022.
- 27 Jun 2022 Planned primary completion date changed from 10 Mar 2022 to 1 Oct 2022.
- 27 Jun 2022 Planned initiation date changed from 1 Dec 2020 to 1 Sep 2021.